GNPX News and Press, Genprex Inc. From 03/20/24

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has entered into definitive agreements. The agreements are for the sale and issuance of 1,542,112 shares of common stock (or prefunded warrants in li...

A look at the top 10 most actives in the United States Fisker Inc. Class A (FSR) fell 9.8% to $0.133 on volume of 209,262,975 shares Ontrak Inc. (OTRK) rose 131.6% to $0.44 on volume of 206,699,914 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 1.7% to $3.65 on volume of 1...

Genprex (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. The company today announced its entry into definitive agreements for the sale and issuance of 1,542,112 shares of its common stock (or prefunded wa...

2024-03-19 08:48:58 ET More on Genprex Genprex to effect 1-for-40 reverse stock split to regain Nasdaq compliance Seeking Alpha’s Quant Rating on Genprex Financial information for Genprex Read the full article on Seeking Alpha For further detai...

Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules PR Newswire AUSTIN, Texas , March 19, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company...

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has received a Notice of Patent Grant from the Korean Patent Office. The patent, which is effective through 2037, covers the use of the companyȁ...

Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers PR Newswire Expands on the previously granted patents covering the use of REQORSA in combination with immune checkpoint inhibitor...

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, will be presenting its research at next month’s 2024 American Association for Cancer Research Annual Meeting. The gathering is slated for Apri...

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting PR Newswire Reqorsa ® Immunogene Thera...

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, is expanding its nonclinical programs into new indications. According to the announcement, the company is expanding through sponsored research agreem...